[ad_1]
President Jair Bolsonaro (non-party) said on Saturday (19) that he was in no rush to buy the Covid-19 vaccine, despite the recent increase in the number of cases and deaths caused by the virus.
“The pandemic is really coming to an end. The numbers have proven it. Now we are in a small increase, what is called a small increase; It can happen. But rushing for the vaccine is not justified, because people’s lives are affected, “said the president in an interview with his own son, Congressman Eduardo Bolsonaro (PSL-SP).
On Thursday (17) Bolsonaro signed an MP (Provisional Measure) that allocates R $ 20 billion to the Ministry of Health, resources that will be used to buy vaccines against Covid-19.
“I’m not in a hurry to spend that money,” the president said in an interview broadcast this Saturday on his son’s YouTube channel.
The funds should be used to finance the national immunization plan against Covid-19. According to the Planalto Palace, the R $ 20 billion will cover “expenses with the purchase of vaccine doses, syringes, needles, logistics, communication and all the expenses that are necessary to vaccinate the population.”
Bolsonaro once again said that vaccination will be voluntary, although the Supreme Court (STF) decided this week that it should be mandatory.
The president maintains that, for a vaccine to be used in Brazil, it must be examined by Anvisa (the National Health Surveillance Agency).
The House this week approved a bill with more flexible rules for the agency to grant temporary authorization for emergency use for the import and distribution of vaccines against the coronavirus.
The agency, according to the bill, has to respond to the request for emergency use of the immunizer within five days. On Monday (14), Anvisa reported that, as soon as it receives the orders from the manufacturers, it will decide on the case within a period of up to ten days.
In addition, to expedite the process, the text approved by the Chamber allows emergency use to be approved by the agency as long as the vaccine has already been approved by agencies in other countries, such as FDA (United States), EMA (European Union) , PMDA. (Japan), NMPA (China), HC (Canada), MHRA (UK).
